[Retracted] A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia

Table 1

Baseline characteristics of trials included in the meta-analysis.

Author	Year	Patients	Mean age (y)	Number (P/C)	PCSK9-mAbs	Control	Drug regimen	Time	Area	Duration
Raal et al. [16]	2015	heFH	51	220/109	Evolocumab	Placebo	140 mg every 2 weeks, 420 mg monthly	Feb 7 to Dec 19, 2013	Australia, Asia, Europe, New Zealand, North America, and South Africa	12 weeks
Raal et al. [17]	2012	heFH	51	111/56	Evolocumab (AMG 145)	Placebo	350 mg-420 mg, every 4 weeks	Aug 2011 to Feb 2012	North America, Western Europe, Hong Kong, Singapore, and South Africa	12 weeks
Ginsberg et al. [15]	2016	heFH	50.6	72/35	Alirocumab	Placebo	150 mg, every 2 weeks	June 2012 to Jan 2015	Canada, the United States, the Netherlands, Russia, and South Africa	78 weeks
Stein et al. [14]	2012	heFH	53.4	62/15	Alirocumab (REGN727)	Placebo	150 mg, 200 mg, and 300 mg, every 4 weeks; then 150 mg every 2 weeks	Jan 18, 2011, to Nov 7, 2011	USA and Canada	12 weeks
Moriarty et al. [13]	2016	heFH	58.7	41/21	Alirocumab	Placebo	150 mg, every 2 weeks	Mar 2015 to Sep 2015	United States and Germany	18 weeks
Raal et al. (2) [18]	2015	hoFH	31	33/16	Evolocumab	Placebo	420 mg, every 4 weeks	Feb 17, 2013, to Jan 31, 2014	North America, Europe, Middle East, and South Africa	12 weeks
Stein et al. (2) [19]	2012	heFH and non-FH	45	101/32	Alirocumab	Placebo	Single-dose study: 50, 100, 150, and 250 mg; multiple-dose study: 50, 100, or 150 mg on days 1, 29, and 43	Nov 2009 to May 2011	Kansas, Miramar, Florida	148 days